Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-14T22:30:05.655Z Has data issue: false hasContentIssue false
  • English
  • Français

Duloxetine in the treatment of melancholic depression

Published online by Cambridge University Press:  24 June 2014

K Kelin
K Kelin*
Affiliation:
Eli Lilly Australia Pty Ltd, Australia
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Abstracts from ‘Brainwaves’— The Australasian Society for Psychiatric Research Annual Meeting 2006, 6–8 December, Sydney, Australia
Information
Acta Neuropsychiatrica , Volume 18 , Issue 6 , December 2006, pp. 294 - 295
Copyright
Copyright © 2006 Blackwell Munksgaard

Background:

Treatment response for melancholic patients may differ from nonmelancholic depressed patients, with broader spectrum antidepressant drugs being required for the melancholic subtype. Outpatients (n = 202) meeting the diagnostic criteria for major depressive disorder (DSM-IV), with HAMD17 >20 and melancholic features, participated in an 8-week, multicenter, open-label, naturalistic, variable dose pilot study (F1J-AY-HMCZ).

Method:

All patients received duloxetine 60 mg/day for the first 4 weeks. In patients not responding by this time, effectiveness of duloxetine treatment was compared between patients who either continued on 60 mg or received a higher, flexible (90-120 mg/ day) dose, for a second 4-week period.

Results:

After the initial 4-week period, 40.6% of patients (n = 82) responded (≥50% reduction from baseline HAMD17) to duloxetine 60 mg/day, and 17.8% (n = 36) achieved formal remission (HAMD17 ≤7) of symptoms. For nonresponders at 4 weeks, no significant differences were detected across the 60-mg and 90- to 120-mg treatment groups in the rates of response (47.9% and 42.9%, respectively) or remission (22.9% and 18.4%) over the next 4 weeks. Overall, 58% of enrolled patients responded to treatment by study completion. Nausea, headache, dry mouth and constipation were the most frequently reported emergent adverse events.

Conclusions:

The overall response rates after 4 and 8 weeks were encouraging for this sample of melancholic patients. In patients who did not respond to duloxetine 60 mg over the first 4 weeks of treatment, increasing to a higher dose in the second month was not associated with any greater clinical benefit.